The Board of Directors of Keros Therapeutics has approved a “poisonous waste pill” in response to the investor’s growing interest in “company control”.
The move comes after certain investors – including an individual who has 11.2% of the outstanding ordinary shares of Keros as of April 6, 2025 – expressed a desire to shape the company’s strategic decisions.
Keros -based Keros said the plan for a limited reduction shareholder is designed to protect the integrity of his current strategic review process, which may include potential sales of the company.
As a result of the announcement, Keros’s shares jumped 13%, reaching $ 11.67 per share on the Open market. The company has confirmed that it has initiated a process for assessing strategic alternatives and plans to provide updates for the process within 60 days of the announcement on April 10.
This update follows a series of challenges facing keros associated with its clinical program Cibotercept for pulmonary arterial hypertension (PAH). In December 2024
Keros suspended the two groups with a larger dose and eventually completed the study in January 2025, citing “the ongoing review of security as a result of new accumulations of the side effects of the pericardial effusion”.
The candidate was positioned as a rival to MSD Pah Drug Winrevair (Sotatercept). US Food and Drug Administration (FDA) Approved WinRevair in March 2024 And it is projected to reach blockbuster status, generating up to $ 6.4 billion in global sales by 2030, according to Globalda, the parent company of Pharmaceutical technology.
Keros’s leading candidate is the TGF-Beta inhibitor, called ELRITERCEPT. The candidate is examined in the ongoing Stage Recovery III (NCT06499285), aimed at anemia -dependent transfusion in very low, low or secondary risky myelodysplastic syndrome (MDS) patients.
In December 2024, Takeda introduced a A deal worth $ 1.3 billion with Caro To further develop, produce and commercialize elritercept around the world outside the mainland China, Hong Kong and Macao. According to the Globalda Center for Intelligence, Elrittercet is projected to generate up to $ 425 million in 2030, if approved.
Keros also promotes its pipeline with KER-065, a DMD muscle dystrophy, which showed positive results at an early stage. The company announced in March 2025 that Kerr-065 was well tolerated in phase I tests, with evidence of inhibiting activation through “tissues of interest”. Following the announcement, Keros said he plans to join the Q3 2025 regulatory authorities, with a DMD trial that is expected to begin in Q1 2026, in anticipation of regulatory feedback.
Source link
